A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

Otlertuzumab is a novel humanized anti-CD37 protein therapeutic. This study evaluated the safety of otlertuzumab administered intravenously to patients with chronic lymphocytic leukemia (CLL). Otlertuzumab was administered weekly for up to 8 weeks followed by 1 dose per month for 4 months ranging fr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Byrd, John C., Pagel, John M., Awan, Farrukh T., Forero, Andres, Flinn, Ian W., Deauna-Limayo, Delva P., Spurgeon, Stephen E., Andritsos, Leslie A., Gopal, Ajay K., Leonard, John P., Eisenfeld, Amy J., Bannink, Jeannette E., Stromatt, Scott C., Furman, Richard R.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2014
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3938145/
https://ncbi.nlm.nih.gov/pubmed/24381226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-07-512137
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires